Botulinum toxin typeA for the treatment of lower urinary tract disorders

International Journal of Urology

Volumn 19, Issue 3, 2012, Pages 202-215

  Yokoyama, Teruhiko ^a   Chancellor, Michael B ^c   Oguma, Keiji ^b   Yamamoto, Yumiko ^b   Suzuki, Tomonori ^b   Kumon, Hiromi ^b   Nagai, Atsushi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder; Botulinum toxin typeA; Detrusor overactivity; Idiopathic; Neurogenic; Prostate; Urethra

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; MUSCLE RELAXANT AGENT;

BLADDER CAPACITY; BLEPHAROSPASM; CERVICAL DYSTONIA; CLOSTRIDIUM BOTULINUM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPHONIA; DYSTONIA; DYSURIA; EPIDIDYMITIS; HEMATURIA; HUMAN; IDIOPATHIC DETRUSOR OVERACTIVITY; IDIOPATHIC DISEASE; IMPAIRED BLADDER EMPTYING; INJECTION SITE PAIN; INTERSTITIAL CYSTITIS; LOWER URINARY TRACT SYMPTOM; MUSCLE WEAKNESS; NEUROGENIC DETRUSOR OVERACTIVITY; NONHUMAN; NYSTAGMUS; OVERACTIVE BLADDER; PAIN ASSESSMENT; PARASYMPATHETIC INNERVATION; PELVIS PAIN SYNDROME; PHASE 3 CLINICAL TRIAL (TOPIC); POSTVOID RESIDUAL URINE VOLUME; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STRABISMUS; TREATMENT RESPONSE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE RETENTION; URODYNAMICS; MALE; PROSTATISM;

BOTULINUM TOXINS, TYPE A; CYSTITIS, INTERSTITIAL; HUMANS; MALE; NEUROMUSCULAR AGENTS; PROSTATISM; URINARY BLADDER, OVERACTIVE;

EID: 84857358284     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02946.x     Document Type: Review

References (80)

1. Sakaguchi G, Kozaki S, Ohishi I. Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JH, Jeljaszewicz J (eds). Bacterial Protein Toxins. Academic Press, London, 1984; 435-43.
2. Oguma K, Inoue K, Fujinaga K etal. Structure and function of Clostridium botulinum progenitor toxin. J. Toxicol. Toxin Rev. 1999; 18: 17-34.
3. Hasegawa K, Watanabe T, Suzuki T etal. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J. Biol. Chem. 2007; 282: 24777-83.
4. Oguma K, Nishikawa A, Sakaguchi Y. C.botulinum. In: Matsumoto K (ed.). Meaning of Pathogenic Bacteria, 4th edn. Iyaku Journal Press, Osaka, 2011; 259-88.
5. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 1991; 324: 1186-94.
6. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000; 55: S29-35.
7. Lee JC, Yokota K, Arimitsu H etal. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. Microbiology 2005; 151: 3739-47.
8. Frevert J. Xeomin®: an innovative new botulinum toxin type A. Eur. J. Neurol. 2009; 16 (Suppl 2): 11-13.
9. Dressler D. Routine use of Xeomin® in patients previously treated with Botox®: long term results. Eur. J. Neurol. 2009; 16 (Suppl 2): 2-5.
10. Lee JC, Yokoyama T, Hwang HJ etal. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity. FEMS Immunol. Med. Microbiol. 2007; 51: 201-11.
11. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol. Rev. 1980; 44: 419-48.
12. Schiavo G, Rossetto O, Santucci A etal. Botulinum neurotoxins are zink proteins. J. Biol. Chem. 1992; 267: 23479-83.
13. Dolly JO, Black J, Williams RS etal. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 1984; 307: 457-60.
14. Blasi J, Chapman ER, Link E etal. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160-3.
15. Dong M, Yeh F, Tepp WH etal. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-6.
16. Smith CP, Franks ME, McNeil BK etal. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J. Urol. 2003; 169: 1896-900.
17. Smith CP, Boone TB, de Groat WC etal. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res. Bull. 2003; 61: 165-71.
18. Datta SN, Roosen A, Pullen A etal. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J. Urol. 2010; 184: 2578-85.
19. Hawthorn MH, Chapple CR, Cock M etal. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br. J. Pharmacol. 2000; 129: 416-19.
20. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action. Eur. Urol. 2003; 43: 1-5.
21. Khera M, Somogyi GT, Kiss S etal. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem. Int. 2004; 45: 987-93.
22. Rapp DE, Turk KW, Bales GT etal. Botulinum toxin type a inhibits calcitonin gene related peptide release from isolated rat bladder. J. Urol. 2006; 175: 1138-42.
23. Chuang YC, Yoshimura N, Huang CC etal. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004; 172: 1529-32.
24. Schurch B, Stohrer M, Kramer G etal. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. 2000; 164 (3 Pt 1): 692-7.
25. Schurch B, de Seze M, Denys P etal. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 2005; 174: 196-200.
26. Ehren I, Volz D, Farrelly E etal. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand. J. Urol. Nephrol. 2007; 41: 335-40.
27. Ginsberg D, Gousse A, Keppenne V etal. Phase 3 efficacy and safety study of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. 2011 American Urological Association Annual Meeting. May 2011, Abstract 1515.
28. Chancellor MB, Patel V, Leng W etal. OnabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: effects on health related quality of life. 2011 Urological Association Annual Meeting. May 2011, Abstract 1518.
29. Cruz F, Herschorn S, Alicotta P etal. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur. Urol. 2011; 60: 742-50.
30. Chancellor MB. Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int. Urol. Nephrol. 2010; 42: 383-91.
31. Karsenty G, Denys P, Amarenco G etal. Botulinum toxin A (botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur. Urol. 2008; 53: 275-87.
32. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur. Urol. 2005; 47: 653-9.
33. Panneck J, Göcking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009; 104: 1246-50.
34. de Paiva A, Meunier FA, Molgo J etal. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA 1999; 96: 3200-5.
35. Haferkamp A, Schurch B, Reitz A etal. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur. Urol. 2004; 46: 784-91.
36. Compérat E, Reitz A, Delcourt A etal. Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur. Urol. 2006; 50: 1058-64.
37. Game X, Castel-Lacanal E, Bentaleb Y etal. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur. Urol. 2008; 53: 613-18.
38. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J. Urol. 2004; 171: 2128-37.
39. Del Popolo G, Filocamo MT, Li Marzi V etal. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur. Urol. 2008; 53: 1013-19.
40. Radziszewski P, Dobronski P, Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A: a pilot study. Neurourol. Urodyn. 2001; 20: 410.
41. Zermann DH, Ishigooka M, Schubert J etal. Trigone and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol. Urodyn. 2001; 20: 412.
42. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 2007; 177: 2231-6.
43. Brubaker L, Richter HE, Visco A etal. Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 2008; 180: 217-22.
44. Flynn MK, Amundsen CL, Perevich M etal. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J. Urol. 2009; 181: 2608-15.
45. Okamura K, Nojiri Y, Ameda K etal. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes. Int. J. Urol. 2011; 18: 483-7.
46. Dmochowski R, Chapple C, Nitti VW etal. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J. Urol. 2010; 184: 2416-22.
47. Anger JT, Weinberg A, Suttorp MJ etal. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J. Urol. 2010; 183: 2258-64.
48. Apostolidis A, Dasgupta P, Denys P etal. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur. Urol. 2009; 55: 100-19.
49. Sahai A, Khan MS, Le Gall N etal. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008; 71: 455-9.
50. Cohen BL, Caruso DJ, Kanagarajah P etal. Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv. Urol. 2009; Article ID 328364.
51. Schmid DM, Sauermann P, Werger M etal. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J. Urol. 2006; 176: 177-85.
52. Popat R, Apostolidis A, Kalsi V etal. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J. Urol. 2005; 174: 984-9.
53. Kessler TM, Danuser H, Schumacher M etal. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol. Urodyn. 2005; 24: 231-6.
54. Schulte-Baukloh H, Weiss C, Stolze T etal. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: 82-7.
55. Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J. Endourol. 2005; 19: 880-2.
56. Schulte-Baukloh H, Weiss C, Stolze T etal. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur. Urol. 2005; 48: 984-90; discussion 990.
57. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur. Urol. 2010; 58: 919-26.
58. Sahai A, Sangster P, Kalsi V etal. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 2008; 103: 630-4.
59. Smith CP, Radziszewski P, Borkowski A etal. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-5; discussion 875.
60. Giannantoni A, Costantini E, Di Stasi SM etal. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur. Urol. 2006; 49: 704-9.
61. Giannantoni A, Mearini E, Del Zingaro M etal. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr. Drug Deliv. 2010; 7: 1-4.
62. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104: 657-61.
63. Tirumuru S, Al-Kurdi D, Latthe P. Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int. Urogynecol. J. 2010; 21: 1285-300.
64. Maria G, Brisinda G, Civello IM etal. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 259-64. discussion 264-5.
65. Kuo HC. Prostate botulinum A toxin injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 670-4.
66. Chuang YC, Chiang PH, Huang CC etal. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66: 775-9.
67. Chuang YC, Chiang PH, Yoshimura N etal. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006; 98: 1033-7; discussion 1337.
68. Crawford ED, Hirst K, Kusek JW etal. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase 2 randomized clinical trial. J. Urol. 2011; 186: 965-70.
69. Guercini F, Giannantoni A, Bard RL etal. Intraprostatic botulinum toxin injection in patients with severe benign prostatic hyperplasia a multicenter feasible study (Abstract). J. Urol. 2005; 173 (Suppl): 376-7.
70. Brisinda G, Cadeddu F, Vanella S etal. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and longterm results. Urology 2009; 73: 90-4.
71. Nishiyama Y, Yokoyama T, Tomizawa K etal. The effects of purified newly developed botulinum neurotoxin type A in the rat prostate. Urology 2009; 74: 436-9.
72. Luján M, Páez A, Llanes L etal. Role of autonomic innervation in rat prostatic structure maintenance: a morphometric analysis. J. Urol. 1988; 160: 1919-23.
73. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J. Urol. 2003; 19: 1520-5.
74. Doggweiler R, Zermann DH, Ishigooka M etal. Botox-induced prostatic involution. Prostate 1998; 37: 44-50.
75. McVary KT, Razzaq A, Lee C etal. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol. Reprod. 1994; 51: 99-107.
76. Apostolidis A, Jacques TS, Freeman A etal. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur. Urol. 2008; 53: 1245-53.
77. Giannantoni A, Di Stasi SM, Nardicchi V etal. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J. Urol. 2006; 175: 2341-4.
78. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol. 2009; 56: 700-6.
79. Nikoobakht M, Daneshpajooh A, Ahmadi H etal. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: initial experience with Dysport. Scand. J. Urol. Nephrol. 2010; 44: 151-7.
80. Oeconomou A, Madersbacher H, Kiss G etal. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur. Urol. 2008; 54: 765-75.